Platelet cytochrome c-oxidase and glutamine synthetase-like protein in patients with mild cognitive impairment

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 112, Issue 2, 2012, Pages 55-58

  Burbaeva, G S H ^a   Boksha, I S ^a   Savushkina, O K ^a   Turishcheva, M S ^a   Tereshkina, E B ^a   Starodubtseva, L I ^a   Gavrilova, S I ^a   Fedorova, Y B ^a   Zhuravin, I A ^a  

^a NONE

Author keywords

Alzheimer's disease; Cytochrome c oxidase; Glutamine synthetase like protein; Mild cognitive impairment syndrome; Platelet markers

Indexed keywords

CYTOCHROME C OXIDASE; GLUTAMATE AMMONIA LIGASE; AMIDE SYNTHASE; GLUTAMINE SYNTHETASE LIKE PROTEIN, HUMAN; GLUTAMINE SYNTHETASE-LIKE PROTEIN, HUMAN; NERVE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; SCORING SYSTEM; BLOOD; EARLY DIAGNOSIS; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; THROMBOCYTE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMIDE SYNTHASES; BLOOD PLATELETS; EARLY DIAGNOSIS; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NERVE TISSUE PROTEINS;

EID: 84863512582     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bailey P. Biological Markers in Alzheimer's Disease. Can J Neurol Sci 2007; 34: (Suppl. 1): 72-76.
2. Belayev N.D., Nalivaeva N.N., Makova N.Z. et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rept 2009; 10: 1: 94-100.
3. Blasko I., Lederer W., Oberbauer H. et al. Measurement of thirteen biological markers in csf of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006; 21: 1: 9-15.
4. Boksha I., Burbaeva G., Savushkina O. et al. Blood proteins as markers and predictors of cognitive deficit in mental pathologies. 30th World Congress Gene-2009. Foshan, China, Abstracts. http://www.bitlifesciences.com/wcg2009/Program.asp
5. Burbaeva G.Sh., Boksha I.S., Turishcheva M.S. et al. Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone. Health 2011; 3: 1: 13-19.
6. Cardoso S.M., Proença M.T., Santos S. et al. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 2004; 25: 1: 105-110.
7. Chouliaras L., Rutten B.P.F., Kenis G. et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010; 90: 4: 498-510.
8. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 1: 15-21.
9. Dubois B, and Albert M.L. Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol 2004; 3: 4: 246-248.
10. Folstein M.F., Folstein S. E, McHugh P.R. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 2: 189-198.
11. Gavrilova S.I., Fedorova Y.B., Roshchina I.F. et al. Prognosis of mild cognitive impairment syndrome: data from a two-year clinical follow-up study. Neurosci Behav Physiol 2008; 38: 2:129-134.
12. Golomb J., Kluger A., Garrard P., Ferris S. Clinician's manual on mild cognitive impairment. Science Press Ltd., London 2001; 56.
13. Harry J., Tilson H.A. Neurodegeneration methods and protocols. Humana Press (Totowa, N.J.) 1999; 74.
14. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011; 29: 1: 26-32.
15. Hye A., Kerr F., Archer N. et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 2005; 373: 1: 1-4.
16. Kim S.M., Song J., Kim S. et al. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. BMC Neurol 2011; 12(11): 51.
17. Marksteiner J. and Humpel C. Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. Exp Gerontol 2009; 44: (6-7), 370-371.
18. McKhann G., Drachman D., Folstein et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
19. Mattsson N., Zetterberg H., Hansson O. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 4: 385-393.
20. Monge-Argilés J.A., Muñoz-Ruiz C., Pampliega-Pérez A. et al. Biomarkers of Alzheimer's disease in the cerebrospinal fluid of Spanish patients with mild cognitive impairment. Neurochem Res 2011; 36: 6: 986-993.
21. Morris J.C. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type. Int Psychogeriatr 1997; 8: 173-176.
22. Pardossi-Piquard R., Petit A., Kawarai T. et al. Presenilin-dependent transcriptional control of the A-degrading enzyme neprilysin by intracellular domains of APP and APLP. Neuron 2005; 46: 541-554.
23. Parker W.D. Jr., Parks J.K. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 1995; 45: (Part. 1): 482-486.
24. Pater C. Mild Cognitive Impairment (MCI) - The novel trend of targeting Alzheimer's disease in its early stages - methodological considerations. Curr Alzheimer Res 2011; 18.
25. Rolstad S., Berg A.I., Bjerke M. et al. Amyloid-42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 2011; 26: 1: 135-142.
26. Rosen W.C., Mohs K.C., Davis K.Z. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
27. Torres L.L., Quaglio N.B., de Souza G.T. et al. Peripheral oxidative stress biomarkers in Mild Cognitive Impairment and Alzheimer's disease. J Alzheimers Dis 2011; 26: 1: 59-68.
28. Visser P.J. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; 67: 1201-1207.